Delhi High Court Compels Union to Explain Delay in Funding Rare‑Disease Transplant for Toddler

The Delhi High Court on Monday issued a formal requisition to the Union Government demanding an immediate written response to a petition filed by the parents of a three‑year‑old girl, whose prognosis depends upon a bone‑marrow transplant whose estimated cost approaches forty lakh rupees. In its order, the bench emphasized that the delay in adjudicating the request not only flouts the constitutional guarantee of the right to life but also undermines the statutory obligation of the central administration to operationalise the National Rare Diseases Policy promulgated in the year two thousand twenty.

The minor, whose parents have identified her condition as a hereditary form of severe combined immunodeficiency, has been counselled by paediatric haematologists that without a suited donor a bone‑marrow transplantation represents the sole therapeutic avenue capable of averting a near‑certain fatality before she reaches the age of five. Medical experts submitted to the court that the total expenditure, encompassing pre‑transplant conditioning, post‑operative intensive care, and lifelong follow‑up, is currently estimated at approximately forty million Indian rupees, a sum that the family, reliant on modest earnings from informal street‑side vending, cannot hope to amass without state assistance.

The petition, filed under Article 32 of the Constitution invoking the writ of mandamus, contends that the central authority, by virtue of its proclaimed commitment to fund rare‑disease treatments through the Ayushman Bharat‑Rare Diseases Programme, has abdicated its duty by failing to disburse the requisite forty lakh rupees within the statutory thirty‑day window stipulated for emergency medical assistance. Counsel for the minors further argued that the Ministry of Health and Family Welfare, in a circular dated fifteen March two thousand twenty‑four, expressly identified bone‑marrow transplant for severe immunodeficiency as a Category‑A intervention eligible for full reimbursement, thereby rendering any bureaucratic reticence tantamount to an arbitrary denial of a constitutionally protected health right.

In a terse reply dated two days prior to the hearing, the Union Ministry articulated that while the scheme indeed earmarks funds for rare disorders, the allocation process necessitates a comprehensive case file, verification by a designated nodal agency, and, critically, the existence of a confirmed donor match, all of which, according to the Ministry, remain incomplete in the present instance. The Ministry’s communiqué, however, omitted any reference to the explicit budgetary provision of forty lakh rupees for the child’s transplant, and the court, noting the incongruity between policy pronouncements and practical implementation, has therefore ordered the Centre to submit a detailed account of the procedural bottlenecks, financial authorisations, and inter‑departmental communications that have hitherto impeded the release of the requested funds.

Observers of public health administration have remarked that the episode lay bare a chronic disjunction between the lofty rhetoric of universal health coverage promulgated in national development plans and the labyrinthine procedural machinery that routinely postpones life‑saving interventions for the most vulnerable citizens. The protracted timeline, extending from the initial diagnosis in September last year to the present judicial intervention, exemplifies a pattern wherein beneficiaries of rare‑disease schemes are compelled to resort to costly litigation, thereby imposing additional financial and emotional burdens that the state ostensibly vows to alleviate.

Does the apparent failure of the Ministry to furnish a prompt, itemised financial sanction for a clearly documented medical emergency reveal a deficiency in the internal audit mechanisms that are supposed to supervise the disbursement of rare‑disease funds under the Ayushman Bharat‑Rare Diseases Programme? Should the statutory thirty‑day timeframe prescribed for emergency health assistance be deemed merely aspirational when, in practice, procedural prerequisites such as donor verification and multi‑agency sign‑off routinely extend the decision‑making horizon well beyond the period required to preserve a child's life? Is the reliance on a single nodal agency for case verification, without mandated parallel review by an independent oversight body, compatible with the principles of transparency and accountability enshrined in the Right‑to‑Health jurisprudence emerging from the Supreme Court's recent pronouncements? What remedial legislative or regulatory measures might be enacted to ensure that budgetary provisions for rare‑disease interventions are not merely symbolic allocations but are operationalised through binding timelines, enforceable performance indicators, and a citizen‑centric grievance redressal mechanism that precludes the necessity of judicial intervention as a default recourse?

Could the introduction of a statutory duty on the Union Health Ministry to publish quarterly, publicly accessible dashboards detailing the status of each rare‑disease funding request, including reasons for any denial, constitute a viable instrument to deter administrative inertia and promote evidentiary accountability? Might the allocation of a specific contingency fund within the central budget, insulated from annual revisions and earmarked exclusively for emergency transplants of children diagnosed with life‑threatening rare conditions, alleviate the fiscal ambiguities that currently permit otherwise eligible cases to languish in procedural limbo? Would the establishment of an independent tribunal, vested with the authority to adjudicate disputes over rare‑disease funding within a prescribed fortnight, reconcile the tension between judicial oversight and administrative discretion, thereby preserving both procedural fairness and the exigent health needs of vulnerable patients? Finally, does the current reliance on ad‑hoc judicial pronouncements to compel the release of funds reflect a systemic inadequacy that could be remedied through statutory reforms mandating automatic fund release upon verification of medical necessity, thus obviating the need for litigants to bear the additional burden of courtroom advocacy?

Published: June 6, 2026